FI93459B - Menetelmä terapeuttisesti käyttökelpoisten 6-aryyli-5,6-dihydroimidatso/2,1-b/tiatsolijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten 6-aryyli-5,6-dihydroimidatso/2,1-b/tiatsolijohdannaisten valmistamiseksi

Info

Publication number
FI93459B
FI93459B FI905788A FI905788A FI93459B FI 93459 B FI93459 B FI 93459B FI 905788 A FI905788 A FI 905788A FI 905788 A FI905788 A FI 905788A FI 93459 B FI93459 B FI 93459B
Authority
FI
Finland
Prior art keywords
6alkyl
aryl
dihydroimidazo
compounds
thiazole derivatives
Prior art date
Application number
FI905788A
Other languages
English (en)
Swedish (sv)
Other versions
FI905788A (fi
FI905788A0 (fi
FI93459C (fi
Inventor
Alfons Herman Marg Raeymaekers
Leopold Frans Corneel Roevens
Laerhoven Willy Joannes Ca Van
Wauwe Jean Pierre Frans Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI905788A0 publication Critical patent/FI905788A0/fi
Publication of FI905788A publication Critical patent/FI905788A/fi
Priority to FI933205A priority Critical patent/FI95248C/fi
Publication of FI93459B publication Critical patent/FI93459B/fi
Application granted granted Critical
Publication of FI93459C publication Critical patent/FI93459C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/40Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
FI905788A 1989-11-24 1990-11-23 Menetelmä terapeuttisesti käyttökelpoisten 6-aryyli-5,6-dihydroimidatso/2,1-b/tiatsolijohdannaisten valmistamiseksi FI93459C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI933205A FI95248C (fi) 1989-11-24 1993-07-14 Tiatsolietanolijohdannaisia, menetelmä niiden valmistamiseksi ja niiden välituotteet

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44084289A 1989-11-24 1989-11-24
US44084289 1989-11-24

Publications (4)

Publication Number Publication Date
FI905788A0 FI905788A0 (fi) 1990-11-23
FI905788A FI905788A (fi) 1991-05-25
FI93459B true FI93459B (fi) 1994-12-30
FI93459C FI93459C (fi) 1995-04-10

Family

ID=23750399

Family Applications (1)

Application Number Title Priority Date Filing Date
FI905788A FI93459C (fi) 1989-11-24 1990-11-23 Menetelmä terapeuttisesti käyttökelpoisten 6-aryyli-5,6-dihydroimidatso/2,1-b/tiatsolijohdannaisten valmistamiseksi

Country Status (25)

Country Link
EP (1) EP0430334B1 (fi)
JP (1) JPH03170487A (fi)
KR (1) KR910009714A (fi)
CN (1) CN1032754C (fi)
AT (1) ATE127795T1 (fi)
AU (1) AU630766B2 (fi)
BG (1) BG60587B1 (fi)
CA (1) CA2028756A1 (fi)
CZ (1) CZ281422B6 (fi)
DE (1) DE69022370T2 (fi)
FI (1) FI93459C (fi)
HU (1) HU206361B (fi)
IE (1) IE67656B1 (fi)
IL (1) IL96435A (fi)
MY (1) MY131024A (fi)
NO (1) NO300065B1 (fi)
NZ (1) NZ236026A (fi)
PL (1) PL165413B1 (fi)
PT (1) PT95978B (fi)
RO (1) RO108869B1 (fi)
RU (1) RU2051153C1 (fi)
YU (1) YU47955B (fi)
ZA (1) ZA909445B (fi)
ZM (1) ZM5390A1 (fi)
ZW (1) ZW17890A1 (fi)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0524055A1 (fr) * 1991-07-19 1993-01-20 Synthelabo Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
US6165253A (en) * 1994-05-23 2000-12-26 New Jersey Institute Of Technology Apparatus for removal of volatile organic compounds from gaseous mixtures
EP1797880A3 (en) * 1999-01-29 2010-04-28 Board Of Trustees Of The University Of Illinois P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant
ATE380548T1 (de) 1999-01-29 2007-12-15 Univ Illinois Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
PL1799269T3 (pl) 2004-09-28 2017-01-31 Quark Pharmaceuticals, Inc. Oligorybonukleotydy i sposoby ich zastosowania do leczenia łysienia, ostrej niewydolności nerek i innych chorób
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
PL2170403T3 (pl) 2007-06-27 2014-09-30 Quark Pharmaceuticals Inc Kompozycje i sposoby hamowania ekspresji genów proapoptotycznych
CN104557979A (zh) * 2013-10-23 2015-04-29 丹阳恒安化学科技研究所有限公司 盐酸左旋咪唑的制备方法
RU2763739C1 (ru) * 2021-06-28 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) (Z)-9-ароил-8-гидрокси-6-(2-гидроксифенил)-2-(((Z)-2-оксоиндолин-3-илиден)гидразоно)-1-тиа-3,6-диазаспиро[4.4]нон-8-ен-4,7-дионы, обладающие противомикробной активностью
WO2023093700A1 (zh) * 2021-11-29 2023-06-01 中国海洋大学 咪唑并噻唑衍生物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU409983B2 (en) * 1965-07-19 1970-12-31 Imperial Chemical Industries Of Australia New Zealand Limited Process for the manufacture of thia zolidines and thiazolidines produced thereby
GB1444743A (en) * 1973-09-20 1976-08-04 Pfizer Ltd 7-substituted imidazo-1,1-b-thiazolium and 9-substituted thiazolo-3,2-a-benzimidazolium derivatives having hypogly caemic and/or growth promotant properties
US4340738A (en) * 1979-06-21 1982-07-20 Janssen Pharmaceutica, N.V. 2,3-Dihydro-imidazo[2,1-b]benzothiazoles

Also Published As

Publication number Publication date
ZW17890A1 (en) 1992-07-08
YU220890A (sh) 1992-12-21
ATE127795T1 (de) 1995-09-15
CZ281422B6 (cs) 1996-09-11
NO905086L (no) 1991-05-27
NO905086D0 (no) 1990-11-23
CN1052117A (zh) 1991-06-12
BG60587B1 (bg) 1995-09-29
DE69022370D1 (de) 1995-10-19
IE904241A1 (en) 1991-06-05
CZ580390A3 (en) 1996-06-12
NZ236026A (en) 1992-03-26
ZM5390A1 (en) 1992-06-30
ZA909445B (en) 1992-07-29
HU907633D0 (en) 1991-06-28
PL165413B1 (pl) 1994-12-30
AU6680990A (en) 1991-05-30
PT95978B (pt) 1998-01-30
NO300065B1 (no) 1997-04-01
KR910009714A (ko) 1991-06-28
CN1032754C (zh) 1996-09-11
AU630766B2 (en) 1992-11-05
PL287907A1 (en) 1992-04-21
EP0430334B1 (en) 1995-09-13
DE69022370T2 (de) 1996-03-14
FI905788A (fi) 1991-05-25
YU47955B (sh) 1996-07-24
IE67656B1 (en) 1996-04-17
HUT59414A (en) 1992-05-28
FI905788A0 (fi) 1990-11-23
PT95978A (pt) 1991-09-13
MY131024A (en) 2007-07-31
RU2051153C1 (ru) 1995-12-27
RO108869B1 (ro) 1994-09-30
FI93459C (fi) 1995-04-10
HU206361B (en) 1992-10-28
IL96435A (en) 1995-03-15
CA2028756A1 (en) 1991-05-25
IL96435A0 (en) 1991-08-16
JPH03170487A (ja) 1991-07-24
EP0430334A1 (en) 1991-06-05

Similar Documents

Publication Publication Date Title
PT89047A (pt) Processo para a preparacao de derivados de piridazinamina
AU3821089A (en) 2-phenyl-purin-6-one derivatives for use as bronchodilators and vasodilators
FI101624B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten N-(3-hydroksi-4-piperidinyyli)(dihydrobentsofuraani-, dihydro-2H-bentsopyraani- tai dihydrobentsodioksiini)karboksamidijohdannaisten valmistamiseksi ja välituote
FI93459B (fi) Menetelmä terapeuttisesti käyttökelpoisten 6-aryyli-5,6-dihydroimidatso/2,1-b/tiatsolijohdannaisten valmistamiseksi
PT90034A (pt) Processo para a preparacao de tetra-hidroimidazo-{1,4}benzodiazepina-2-onas
DK361587D0 (da) Thiazolyleddikesyrederivater og fremgangsmaader til fremstilling deraf
NO179553C (no) Analogifremgangsmåte for fremstilling av antirhinovirale alkylfenoletre
PT94036A (pt) Processo para a preparacao de piridazinaminas anti-rinovirais
FI894125A0 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisen 3-piperidinyyli-indatsolin valmistamiseksi

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed
MM Patent lapsed

Owner name: JANSSEN PHARMACEUTICA N.V.